Boston Scientific Target of Unusually Large Options Trading (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw unusually large options trading activity on Wednesday. Stock investors purchased 65,788 put options on the stock. This represents an increase of approximately 205% compared to the average daily volume of 21,596 put options.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gerber Kawasaki Wealth & Investment Management lifted its stake in shares of Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC increased its position in shares of Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after acquiring an additional 100 shares during the period. Claret Asset Management Corp grew its stake in shares of Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 102 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its position in Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares during the last quarter. Finally, Scotia Capital Inc. increased its stake in shares of Boston Scientific by 0.7% during the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after buying an additional 104 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Positive clinical data and regulatory wins that support the company’s minimally invasive portfolio (WATCHMAN FLX, EKOS) and broaden procedure use — supportive for long‑term growth. Are Boston Scientific’s (BSX) New Trial Wins Quietly Redefining Its Minimally Invasive Care Advantage?
• Positive Sentiment: FDA 510(k) clearance for the Asurys Fluid Management System — a near‑term commercial catalyst in endoscopic urology. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Several analysts/research notes remain constructive (RBC Outperform, Needham reaffirmed Buy, others retain positive views) — provides some support despite recent weakness. Boston Scientific (NYSE:BSX) Earns “Outperform” Rating from Royal Bank Of Canada
• Neutral Sentiment: Longer‑term analyst commentary and equity research pieces highlight BSX as a growth/compounding story, useful context but not immediate drivers. Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Investor pieces and deep‑dive commentary (Seeking Alpha) frame BSX’s transition from hypergrowth to durable compounding — helpful for longer‑term investors but mixed near term. Boston Scientific: From Hypergrowth To Durable Compounding
• Negative Sentiment: Watchman trial data prompted investor concern about stroke outcomes and growth prospects for that franchise; that reaction contributed to a steep share price drop and move to multi‑month/52‑week lows. Boston Scientific Stock Sinks to 2-Year Low. Why Wall Street Is Souring on Trial Data.
• Negative Sentiment: Raymond James downgraded the stock and cut estimates citing weaker trends in U.S. electrophysiology and Watchman — the downgrade amplified selling pressure. Raymond James downgrades Boston Scientific but long-term story remains intact
• Negative Sentiment: Multiple law firms have filed or issued investor alerts about securities‑class‑action claims tied to disclosures between July 23, 2025 and Feb 3, 2026 (lead plaintiff deadline May 4, 2026) — increased litigation risk and headline noise that can pressure the share price. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. Morgan Stanley lowered their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Finally, Evercore reduced their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $104.36.

Boston Scientific Price Performance

NYSE BSX traded down $0.74 during trading hours on Wednesday, hitting $62.01. The company had a trading volume of 13,695,060 shares, compared to its average volume of 15,926,059. The firm has a 50 day simple moving average of $76.37 and a 200 day simple moving average of $90.03. Boston Scientific has a 52 week low of $61.24 and a 52 week high of $109.50. The firm has a market capitalization of $92.16 billion, a price-to-earnings ratio of 31.95, a PEG ratio of 0.97 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.